Here, we focused on currently available TKI for BCR-ABL1-positive ALL, including bosutinib, imatinib, dasatinib, nilotinib, ponatinib and the novel first-in-class selective allosteric ABL myristoyl pocket (STAMP) inhibitor asciminib, which is currently being tested for BCR-ABL1-positive ALL, but not yet approved [19]. The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.